Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heavy metal containing doai
Reexamination Certificate
1999-11-18
2002-12-24
Gerstl, Robert (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heavy metal containing doai
Reexamination Certificate
active
06498189
ABSTRACT:
BACKGROUND OF THE INVENTION
The invention relates to anti-thiol reagents which inhibit enzyme activity of cell-associated protein disulfide isomerase (PDI) by oxidizing or blocking PDI active site vicinal thiol groups which normally participate in disulfide bond rearrangement of PDI substrates. Inhibition of this PDI function is particularly useful in blocking PDI-mediated entry of HIV or other virions into a host cell.
The present invention also relates to anti-inflammatory agents.
The invention further relates to an assay for the identification of such PDI inhibitors based on the discovery that inhibitors of the invention also induce shedding of the leukocyte L-selectin adhesion molecule.
The invention further relates to the use of calmodulin antagonist reagents to induce L-selectin shedding.
1. Field of Art
PDI (protein disulfide isomerase) is a constitutive intracellular protein that is also found to be expressed on the surface of many mammalian cell types, including immune system cells, hepatocytes, and platelets. Like other members of the thyredoxin superfamily of proteins, PDI is a multifunctional redox-sensitive protein that catalyzes oxidation-reduction reactions via a vicinal dithiol-dependent disulfide-sulfhydryl interchange between its internal vicinal dithiol (Cys-Gly-His-Cys) active sites and the disulfide bonds of its substrates to promote their reconfiguration. PDI recognizes the side chains of cysteine residues in its substrates, and it is its two vicinal dithiol groups, two on each of two identical PDI subunits, that are critical for its enzymatic isomerase function, in particular its broad specificity for correcting the configuration of a large spectrum of proteins as needed. For example, PDI is present in the endoplasmic reticulum of most cells, where it is believed to mediate co- and post-translational modifications of nascent proteins with incorrect sulfide bonds; it is also present in certain protein complexes such as triglyceride transfer protein complex (MTP) wherein it maintains the complex in a catalytically-active state and inhibits complex aggregation. Membrane PDI catalyzes the cleavage of disulfide bonds during the earliest stages of endocytosis, and activates diphtheria toxin by catalyzing cleavage of this disulfide-linked dimer. PDI also catalyzes the isomerization of thrombospondin (TSP) disulfide bonds, thereby profoundly modulating TSP-ligand binding activity. Both TSP and PDI are released by activated platelets; PDI is also released by degranulated neutrophils (
J Cell Physiol
. 144: 280, 1990).
Other known PDI functions include the recognized ability of PDI to modulate certain adhesive interactions. While PDI isomerase activity affects, for example, the adhesive properties of TSP, PDI is additionally a “chaperone” for some proteins by means independent of its catalytic activity. One of these chaperone functions has been attributed to PDI binding in a complex formation with proteins which have a tendency to aggregate in the denatured state. Association with PDI prevents this aggregation by promoting appropriate folding of the associated protein. PDI in MTP complexes inhibits MTP aggregation, and a PDI homolog (cognin) plays a role in the adhesion-dependent aggregation of retinal cells.
2. Discussion of Related Art
Of particular relevance to the present invention is the involvement of PDI in the shedding of the human thyrotropin (TSH) receptor ectodomain (
Biochem,
35:14800, 1996). In a two-step process, a matrix metalloproteinase first cleaves the receptor into two subunits (an &agr;-extracellular subunit and a &bgr;-transmembrane subunit) linked by a disulfide bridge. The (&agr;-extracellular subunit is then shed from the cell membrane as a result of PDI-mediated reduction of the disulfide bridge(s) connecting it to the &bgr;-transmembrane subunit. However, in contrast to the PDI-mediated L-selectin shedding mechanism according to the present invention, the TSH shedding mechanism requires PDI isomerase activity, and inhibition of PDI activity with known PDI inhibitors such as DTNB (5,5′-dithiobis(2-nitrobenzoic acid), bacitracin, or anti-PDI antibodies to prevent the shedding (release) of the TSH &agr;-subunit.
Also of relevance is the known ability of PDI to mediate transmembrane carriage of proteins and virions into cells by rearrangement of their disulfide bonds. For example, the attachment of HIV to its host cell surface receptor CD4 via the viral glycoprotein gp 120 triggers a conformational change in gp 120/gp 41 resulting from a rearrangement of its critical disulfide bonds as catalyzed by PDI. Known PDI inhibitors (e.g., bacitracin, anti-PDI antibodies) block HIV entry into the cell cytoplasm to some extent, but they are very weak inhibitors of PDI isomerase activity in this clinical application (
PNAS USA
91: 4559, 1994). The use of another known PDI inhibitor, DTNB (supra) to inhibit viral penetration into cells has been described (U.S. Pat. No. 5,532,154 to Brown); however, the recited activity of this compound in preventing HIV entry into cells is attributed by the patentee to inactivation of “virus-derived thiol reductase/protein disulfide isomerase”, presumably encoded by and present on the virus itself.
The interaction of arsine oxide with certain proteins having active vicinal dithiol sites which undergo catalytic conversion to disulfides to form stable dithioarsenic derivatives is described in
Anal. BioChem
212: 325-334 (1993). This reactivity was used by the authors to separate dithiols from monothiols and also from dithiol-containing proteins with low-affinity for arsine oxide.
SUMMARY OF THE PRESENT INVENTION
In a first aspect, the present invention provides a compound having the formula:
wherein each of R
1
and R
2
is thioalkyl sulfonate, thioalkyl amine, alkyl sulfonate or R
1
and R
2
together are the same alkyl sulfonate; and each of R
3
, R
4
and R
5
is nothing, H, alkyl, alkyl sulfonate, or aromatic sulfonate.
In a second aspect, the present invention provides a compound having the formula:
wherein each of E
1
and E
2
, is thioalkyl sulfonate, thioalkyl amine, alkyl sulfonate or E
1
and E
2
together are the same alkyl sulfonate.
In a third aspect, the present invention provides a method for treating an inflammatory disease comprising: administering an anti-inflammatory agent to an individual in an amount sufficient to reduce an inflammation in the individual, wherein the anti-inflammatory agent comprises at least one PDI inhibitor.
In a fourth aspect, the present invention provides a method for treating an inflammatory disease comprising: administering an anti-inflammatory agent to an individual in an amount sufficient to reduce an inflammation in the individual, wherein the anti-inflammatory agent comprises at least one calmodulin antagonist.
REFERENCES:
patent: 5532154 (1996-07-01), Brown
patent: 98/51297 (1998-11-01), None
Roussin European J. of Pharmacology 322 (1997) 91-6.*
Kalef, E. et al., Arsenical-Based Affinity Chromatography of Vicinal Dithiol-Containing Proteins: Purification of L1210 Leukemia Cytoplasmic Proteins and the Recombinant Rat c-erb A betal T3 Receptor, Analytical Biochemistry 1993, vol. 212, pp. 325-334.
Kahn et al., “Calmodulin Regulates L-Selectin Adhesion Molecule Expression and Function through a Protease-Dependent Mechanism,”Cell,vol. 92, 809-818, Mar. 20, 1998.
Strausbaugh et al., “Painful stimulation suppresses joint inflammation by inducing shedding of L-selectin from neutrophils,”Nature Medicine, vol. 5, No. 9, Sep. 1999.
Bennett Teresa A.
Rogelj Snezna
Sklar Larry A.
Gerstl Robert
Jagtiani + Guttag
University of New Mexico
LandOfFree
Method for induction of L-selectin shedding does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for induction of L-selectin shedding, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for induction of L-selectin shedding will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2937992